ZandCellZandCell
  • HOME
  • About
    • About
    • News Releases
  • Programs
  • Science
  • Apply
  • Contact
  • Login

    Lost your password?

  • 0
    Cart
  1. Home
  2. B. C. girl with leukemia seeks Christmas stem cell donor – DigitalJournal.com
  3. NEWS

NEWS

Cyborg bacteria turn sunlight into useful chemicals – UC Berkeley

Continue reading

2017-08-23 Michael Zand NEWS

Kite Pharma Asks FDA to Pave Way Toward It Holding Clinical Trials of Its Myeloma Therapy KITE-585 – Myeloma Research News


UC Berkeley

Cyborg bacteria turn sunlight into useful chemicals
UC Berkeley
“Synthetic biology and the ability to expand the product scope of CO2 reduction will be crucial to poising this technology as a replacement, or one of many replacements, for the petrochemical industry,” he said. Sakamoto and Yang presented their work …
‘Cyborg’ bacteria beat plants at their own gameChemistry World (subscription)
Semiconductor nanoparticles give bacteria a boostThe Engineer

all 11 news articles »

Continue reading

2017-08-23 Michael Zand NEWS

New CAR-T drug for leukemia, while effective, is ‘going to cost a fortune’ – STAT


Myeloma Research News

Kite Pharma Asks FDA to Pave Way Toward It Holding Clinical Trials of Its Myeloma Therapy KITE-585
Myeloma Research News
Because the protein is crucial to myeloma cells’ survival and growth, it is a good target for chimeric antigen receptor T-cell treatments, also known as CAR T-cell therapies. Those therapies use a patient’s own immune cells to combat their disease. The …
Kite Pharma, Inc. (NASDAQ:KITE) Traded 21.0% Above Its 50 Day AverageModern Readers
Kite Pharma, Inc. (NASDAQ:KITE) Stock Closed Much Higher Than …HugoPress
Kite Pharma, Inc. (NASDAQ:KITE) Traded Significantly Above Its 50 …Highlight Press
Finance Daily
all 21 news articles »
Continue reading

2017-08-23 Michael Zand NEWS

Global Stem Cell Market SWOT Analysis by Application, Product Types and Regions with Forecast to 2022 – Medgadget (blog)

DailyCommerceNewsGlobal Stem Cell Market SWOT Analysis by Application, Product Types and Regions with Forecast to 2022Medgadget (blog)The Stem Cell Market Research Report Forecast 2017-2022 is a valuable source of insightful data for business strategis… Continue reading

2017-08-23 Michael Zand NEWS

Profit finally in sight for gene therapy specialist Oxford Bio – Reuters

Profit finally in sight for gene therapy specialist Oxford BioReutersLONDON (Reuters) – After 20 years of losses, gene therapy specialist Oxford BioMedica is at last close to achieving its first profit thanks to the success of Novartis with a pioneerin… Continue reading

2017-08-23 Michael Zand NEWS

Profit finally in sight for gene therapy specialist Oxford Bio – Reuters

Profit finally in sight for gene therapy specialist Oxford BioReutersLONDON (Reuters) – After 20 years of losses, gene therapy specialist Oxford BioMedica is at last close to achieving its first profit thanks to the success of Novartis with a pioneerin… Continue reading

2017-08-23 Michael Zand NEWS

Profit finally in sight for gene therapy specialist Oxford Bio – WHTC

Profit finally in sight for gene therapy specialist Oxford BioWHTCLONDON (Reuters) – After 20 years of losses, gene therapy specialist Oxford BioMedica is at last close to achieving its first profit thanks to the success of Novartis with a pioneering c… Continue reading

2017-08-23 Michael Zand NEWS

Profit finally in sight for gene therapy specialist Oxford Bio – WHTC

Profit finally in sight for gene therapy specialist Oxford BioWHTCLONDON (Reuters) – After 20 years of losses, gene therapy specialist Oxford BioMedica is at last close to achieving its first profit thanks to the success of Novartis with a pioneering c… Continue reading

2017-08-23 Michael Zand NEWS
  • 1
  • …
  • 1,318
  • 1,319
  • 1,320
  • 1,321
  • 1,322
  • …
  • 3,595
Recent Posts
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Шведская компания ZandCell поставит 160 млн доз вакцины от COVID-19 в несколько стран мира 2021-07-22
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
About Us

ZandCell is a biotechnology company pioneering the advancements and therapeutic applications of Stem Cell Therapy. Our Technology is called “Regenerate”.

SiteLock
Contact Info
+1-702-425-9049
+46-736-779970
info@zandcell.com
Find us on map


Latest News
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Official PayPal Seal


© 2024 ZandCell. All Rights Reserved.
  • About
  • Programs
  • Science
  • Privacy Policy
  • Contact
  • RSS
  • Send us email
  • Follow us on Twitter
  • Follow us on Facebook
  • Follow Us on Linkedin
  • Call us via Skype
  • Follow Us on Instagram
  • Subscribe our YouTube Channel
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

STAT

New CAR–T drug for leukemia, while effective, is ‘going to cost a fortune’
STAT
The treatment, CTL019, belongs to a new class of medications called CAR–T cell therapies, which involve harvesting patients’ immune cells and genetically altering them to kill cancer. It’s been tested in patients whose leukemia has relapsed in spite of …

and more »